The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
Open accessAbstract
Stem-like T cells mediate response: Adoptive cell transfer (ACT) is a type of immunotherapy that uses a patient's own T lymphocytes to recognize and attack cancer. ACT has been effective in treating certain patients with metastatic melanoma and is being applied to treat some epithelial cancers. Krishna et al. investigated why some cancer patients respond to ACT, whereas others do not. They identified a population of CD8 + T cells that had stem-like surface markers that were associated with effective tumor cell killing and favorable response of melanoma patients to ACT. Only a small subset of T cells specific against tumor mutations were found in this stem-like state, whereas most mutation-reactive T cells were terminally differentiated. These findings could be of value in improving cancer immunotherapy outcomes. Science , this issue p. 1328
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Self-citationHalko, N., Martinsson, P. G., & Tropp, J. A. (2011) · SIAM Review · doi:10.1137/090771806 · Cited by 4,002
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Self-citation
Cited by
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
From bulk, single-cell to spatial RNA sequencing
Li, X., & Wang, C.-Y. (2021) · International Journal of Oral Science · doi:10.1038/s41368-021-00146-0 · Cited by 605
Huang, A. C., & Zappasodi, R. (2022) · Nature Immunology · doi:10.1038/s41590-022-01141-1 · Cited by 571
Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma
Oliveira, G., Stromhaug, K., Klaeger, S., Kula, T., Frederick, D. T., Le, P. M., Forman, J., Huang, T., Li, S., Zhang, W., et al. (2021) · Nature · doi:10.1038/s41586-021-03704-y · Cited by 558
Dynamics and specificities of T cells in cancer immunotherapy
Oliveira, G., & Wu, C. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00560-y · Cited by 525
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Albelda, S. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 517
Huang, Q., Wu, X., Wang, Z., Chen, X., Wang, L., Lu, Y., Xiong, D., Liu, Q., Tian, Y., Lin, H., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.020 · Cited by 486
Lactate and lactylation in cancer
Chen, J., Huang, Z., Chen, Y., Tian, H., Chai, P., Shen, Y., Yao, Y., Xu, S., Ge, S., & Jia, R. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02082-x · Cited by 477
Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers
Lowery, F. J., Krishna, S., Yossef, R., Parikh, N. B., Chatani, P. D., Zacharakis, N., Parkhurst, M. R., Levin, N., Sindiri, S., Sachs, A., et al. (2022) · Science · doi:10.1126/science.abl5447 · Cited by 447
Self-citationCreelan, B. C., Wang, C., Teer, J. K., Toloza, E. M., Yao, J., Kim, S., Landin, A. M., Mullinax, J. E., Saller, J. J., Saltos, A. N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01462-y · Cited by 428
Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity
Feng, Q., Liu, Z., Yu, X., Huang, T., Chen, J., Wang, J., Wilhelm, J., Li, S., Song, J., Li, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32521-8 · Cited by 419
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
Voabil, P., de Bruijn, M., Roelofsen, L. M., Hendriks, S. H., Brokamp, S., van den Braber, M., Broeks, A., Sanders, J., Herzig, P., Zippelius, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01398-3 · Cited by 380
Prokhnevska, N., Cardenas, M. A., Valanparambil, R. M., Sobierajska, E., Barwick, B. G., Jansen, C., Reyes Moon, A., Gregorova, P., delBalzo, L., Greenwald, R., et al. (2023) · Immunity · doi:10.1016/j.immuni.2022.12.002 · Cited by 365
Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355
Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity
Prinzing, B., Zebley, C. C., Petersen, C. T., Fan, Y., Anido, A. A., Yi, Z., Nguyen, P., Houke, H., Bell, M., Haydar, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh0272 · Cited by 349
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
Steffin, D., Ghatwai, N., Montalbano, A., Rathi, P., Courtney, A. N., Arnett, A. B., Fleurence, J., Sweidan, R., Wang, T., Zhang, H., et al. (2025) · Nature · doi:10.1038/s41586-024-08261-8 · Cited by 289
Vitanza, N. A., Wilson, A. L., Huang, W., Seidel, K., Brown, C., Gustafson, J. A., Yokoyama, J. K., Johnson, A. J., Baxter, B. A., Koning, R. W., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0750 · Cited by 279
Promises and challenges of adoptive T-cell therapies for solid tumours
Morotti, M., Albukhari, A., Alsaadi, A., Artibani, M., Brenton, J. D., Curbishley, S. M., Dong, T., Dustin, M. L., Hu, Z., McGranahan, N., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01353-6 · Cited by 269
Giles, J. R., Ngiow, S. F., Manne, S., Baxter, A. E., Khan, O., Wang, P., Staupe, R., Abdel-Hakeem, M. S., Huang, H., Mathew, D., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01338-4 · Cited by 264
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Chowell, D., Yoo, S.-K., Valero, C., Pastore, A., Krishna, C., Lee, M., Hoen, D., Shi, H., Kelly, D. W., Patel, N., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01070-8 · Cited by 260
Challenges and new technologies in adoptive cell therapy
Zhang, P., Zhang, G., & Wan, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01492-8 · Cited by 259
Collier, J. L., Weiss, S. A., Pauken, K. E., Sen, D. R., & Sharpe, A. H. (2021) · Nature Immunology · doi:10.1038/s41590-021-00949-7 · Cited by 237
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers
Hanada, K.-I., Zhao, C., Gil-Hoyos, R., Gartner, J. J., Chow-Parmer, C., Lowery, F. J., Krishna, S., Prickett, T. D., Kivitz, S., Parkhurst, M. R., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.03.012 · Cited by 200
Self-citationOmatsu, M., Nakanishi, Y., Iwane, K., Aoyama, N., Duran, A., Muta, Y., Martinez-Ordoñez, A., Han, Q., Agatsuma, N., Mizukoshi, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41095-y · Cited by 109
Maschan, M., Caimi, P. F., Reese-Koc, J., Sanchez, G. P., Sharma, A. A., Molostova, O., Shelikhova, L., Pershin, D., Stepanov, A., Muzalevskii, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27312-6 · Cited by 88
SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
López-Cobo, S., Fuentealba, J. R., Gueguen, P., Bonté, P.-E., Tsalkitzi, K., Chacón, I., Glauzy, S., Bohineust, A., Biquand, A., Silva, L., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1350 · Cited by 72
Engineering Nano‐Therapeutics to Boost Adoptive Cell Therapy for Cancer Treatment
Zheng, C., Zhang, J., Chan, H. F., Hu, H., Lv, S., Na, N., Tao, Y., & Li, M. (2021) · Small Methods · doi:10.1002/smtd.202001191 · Cited by 61
Metadata
- Authors
- Krishna, S., Lowery, F. J., Copeland, A. R., Bahadiroglu, E., Mukherjee, R., Jia, L., Anibal, J. T., Sachs, A., Adebola, S. O., Gurusamy, D., Yu, Z., Hill, V., Gartner, J. J., Li, Y. F., Parkhurst, M., Paria, B., Kvistborg, P., Kelly, M. C., Goff, S. L., Altan-Bonnet, G., Robbins, P. F., & Rosenberg, S. A.
- Venue
- Science
- Published
- 2020-12-11
- Volume
- 370
- Issue
- 6522
- Pages
- 1328-1334
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3111462718
- Cited by
- 547
- References
- 65
- FWCI
- 19.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.